Cardiovascular Revascularization Medicine
Volume 9, Issue 3 , Pages 166-178 , July 2008

Role of urotensin II in atherosclerotic cardiovascular diseases

  • Rajbabu Pakala

      Affiliations

    • Corresponding Author InformationGHRB 313, 108 Irving Street, NW, Suite 4B-1, Washington, DC 20010, USA. Tel.: +1 202 877 3867; fax: +1 202 877 3997.

Received 29 November 2007 ,Revised 24 January 2008 ,Accepted 5 February 2008.

References 

  1. Colton JM, Yano K, Waugh D, Hazon N. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J Exp Zool. 1996;275:226–238
  2. Douglas SA, Sulpizio AC, Piercy V, Saraju HM, Ames RS, Aiyar NV, et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol. 2000;131:1262–1274
  3. Guerrini R, Camarda V, Marzola E, Arduin M, Calo G, Spagnol M, et al. Structure–activity relationship study on human urotensin II. J Pept Sci. 2005;11:85–90
  4. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA. 1998;95:15803–15808
  5. Russell FD, Kearns P, Toth I, Molenaar P. Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro. J Pharmacol Exp Ther. 2004;310:209–214
  6. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic , et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401:282–286
  7. Douglas SA, Ohlstein EH. Urotensin receptors. In:  Girdlestone D editors. The IUPHAR Compendium of Receptor Characterization and Classification. London: IUPHAR Media; 2000;p. 365–372
  8. Elshourbagy NA, Douglas SA, Shabon U, Harrison S, Duddy G, Sechler JL, et al. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol. 2002;136:9–22
  9. Suzuki S, Wenyi Z, Hirai M, Hinokio Y, Suzuki C, Yamada T, et al. Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides. 2004;25:1803–1808
  10. Protopopov A, Kashuba V, Podowski R, Gizatullin R, Sonnhammer E, Wahlestedt C, et al. Assignment of the GPR14 gene coding for the G-protein-coupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridization. Cytogenet Cell Genet. 2000;88:312–313
  11. Sugo T, Murakami Y, Shimomura Y, Harada M, Abe M, Ishibashi Y, et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun. 2003;310:860–868
  12. Mori M, Fujino M. Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain. Peptides. 2004;25:1815–1818
  13. Russel FD, Molenaar P, O'Brien DM. Cardio-stimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol. 2001;132:5–9
  14. Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator small arteries. Br J Pharmacol. 2000;130:1865–1870
  15. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol. 2000;131:441–446
  16. Behm DJ, Harrison SM, Ao Z, Maniscalco K, Pickering SJ, Grau EV, et al. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol. 2003;139:464–472
  17. Camarda V, Rizzi A, Calo G, Gendron G, Perron SI, Kostenis E, et al. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch. Pharmacol. 2002;365:141–149
  18. Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol. 2002;135:25–27
  19. Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res. 2002;53:341–347
  20. Affolter JT, Newby DE, Wilkinson IB, Winter MJ, Balment RJ, Webb DJ. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol. 2002;54:617–621
  21. Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol. 2001;132:1625–1629
  22. Lin Y, Tsuchihashi T, Matsumura K, Abe I, Iida M. Central cardiovascular action of urotensin II in conscious rats. J Hypertens. 2003;21:159–165
  23. Ishihata A, Sakai M, Katano Y. Vascular contractile effect of urotensin II in young and aged rats: influence of aging and contribution of endothelial nitric oxide. Peptides. 2006;27:80–86
  24. Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation. 2004;109:1212–1214
  25. Sondermeijer B, Kompa A, Komesaroff P, Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens. 2005;18:1195–1199
  26. Gibson A. Complex effects of Gillichthys urotensin II on rat aortic strips. Br J Pharmacol. 1987;91:205–212
  27. Gray GA, Jones MR, Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci. 2001;69:175–180
  28. Katano Y, Ishihata A, Aita T, Ogaki T, Horie T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol. 2000;402:R5–R7
  29. Lacza Z, Busija DW. Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. Life Sci. 2006;78:2763–2766
  30. Zhang AY, Chen YF, Zhang DX, Yi FX, Qi J, Andrade-Gordon P, et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol. 2003;285:F792–F798
  31. Douglas SA, Ashton DJ, Sauermelch CF, Coatney RW, Ohlstein DH, Ruffolo MR, et al. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol. 2000;36:S163–S166
  32. Hillier C, Berry C, Petrie MC, O'Dwyer PJ, Hamilton C, Brown A, et al. Effects of urotensin II in human arteries and veins of varying caliber. Circulation. 2001;103:1378–1381
  33. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol. 2001;280:H925–H928
  34. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, et al. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol. 2000;130:201–204
  35. Ishihata A, Ogaki T, Aita T, Katano Y. Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. Eur J Pharmacol. 2005;523:119–126
  36. Behm DJ, Doe CP, Johns DG, Maniscalco K, Stankus GP, Wibberley A, et al. Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:274–280
  37. Lin Y, Tsuchihashi T, Matsumura K, Fukuhara M, Ohya Y, Fujii K, et al. Central cardiovascular action of urotensin II in spontaneously hypertensive rats. Hypertens Res. 2003;26:839–845
  38. Watson , Lambert GW, Smith KJ, May CN. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension. 2003;42:373–379
  39. Song W, Abdel-Razik AE, Lu W, Ao Z, Johns DG, Douglas SA, et al. Urotensin II and renal function in the rat. Kidney Int. 2006;69:1360–13688
  40. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens. 2004;22:1341–1344
  41. Thompson JP, Watt P, Sanghavi S, Strupish JW, Lambert DG. A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg. 2003;97:1501–1503
  42. Rdzanek A, Filipiak KJ, Karpiński G, Grabowski M, Opolski G. Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension. Int J Cardiol. 2006;110:175–178
  43. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens. 2001;19:2185–2190
  44. Yi L, Gu YH, Wang XL, An LZ, Xie XD, Shao W, et al. Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. J Int Med Res. 2006;34:272–283
  45. Ong KL, Wong LY, Man YB, Leung RY, Song YQ, Lam KS, et al. Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides. 2006;27:1659–1667
  46. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci. 2003;104:1–5
  47. Sheridan MA, Plisetskaya EM, Bern HA, Gorbman A. Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. en Comp Endocrinol. 1987;66:405–414
  48. Sauzeau V, Mellionnec EL, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res. 2001;88:1102–1104
  49. Silvestre RA, Egido EM, Hernández R, Leprince J, Chatenet D, Tollemer H, et al. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol. 2004;151:803–809
  50. Silvestre RA, Rodriguez-Gallardo J, Egido EM, Marco J. Inhibition of insulin release by urotensin II—a study on the perfused rat pancreas. Horm Metab Res. 2001;33:379–381
  51. Du W, Sun H, Wang H, Qiang B, Shen Y, Yao Z, et al. Confirmation of susceptibility gene loci on chromosome 1 in northern China Han families with type 2 diabetes. Chin Med J. 2001;114:876–878
  52. Mori Y, Otabe S, Dina C, Yasuda K, Populaire C, Lecoeur C, et al. Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate loci on 7p and 11p. Diabetes. 2002;51:1247–1255
  53. Sun HX, Du WN, Zuo J, Wu GD, Shi GB, Shen Y, et al. The association of two single nucleotide polymorphisms in PRKCZ and UTS2 respectively with type 2 diabetes in Han people of northern China. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002;24:223–227
  54. Zhu F, Ji L, Luo B. The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population. Zhonghua Yi Xue Za Zhi. 2002;82:1473–1475
  55. Wenyi Z, Suzuki S, Hirai M, Hinokio Y, Tanizawa Y, Matsutani A, et al. Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia. 2003;46:972–976
  56. Charles CJ, Rademaker MT, Richards AM, Yandle TG. Urotensin II: evidence for cardiac, hepatic and renal production. Peptides. 2005;26:2211–2214
  57. Gartlon J, Parker F, Harrison DC, Douglas SA, Ashmeade TE, Riley GJ, et al. Central effects of urotensin-II following ICV administration in rats. Psychopharmacology (Berl). 2001;155:426–433
  58. Williams G, Bing C, Cai XJ, Harrold JA, King PJ, Liu XH. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav. 2001;74:683–701
  59. Do-Rego JC, Chatenet D, Orta MH, Naudin B, Le Cudennec C, Leprince J, et al. Behavioral effects of urotensin-II centrally administered in mice. Psychopharmacology (Berl). 2005;183:103–117
  60. Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:238–250
  61. Birker-Robaczewska M, Boukhadra C, Studer R, Mueller C, Binkert C, Nayler O. The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res. 2003;23:289–305
  62. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol. 2005;25:519–525
  63. Mallamaci F, Cutrupi S, Pizzini P, Tripepi G, Zoccali C. Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens. 2006;19:505–510
  64. Dai HY, Kang WQ, Wang X, Yu XJ, Li ZH, Tang MX, et al. The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. Regul Pept. 2007;140:88–93
  65. Hassan GS, Douglas SA, Ohlstein EH, Giaid A. Expression of urotensin-II in human coronary atherosclerosis. Peptides. 2005;26:2464–2472
  66. Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis. 2004;176:117–123
  67. Suguro T, Watanabe T, Ban Y, Kodate S, Misaki A, Hirano T, et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens. 2007;20:211–217
  68. Wang ZJ, Shi LB, Xiong ZW, Zhang LF, Meng L, Bu DF, et al. Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout. Peptides. 2006;27:858–863
  69. Rakowski E, Hassan GS, Dhanak D, Ohlstein EH, Douglas SA, Giaid A. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol. 2005;39:785–791
  70. Watanabe T, Takahashi K, Kanome T, Hongo S, Miyazaki A, Koba S, et al. Human urotensin-II potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells: comparison with other vasoactive agents and hydrogen peroxide. Hypertens Res. 2006;29:821–831
  71. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation. 2001;104:16–18
  72. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens. 2001;19:2191–2196
  73. Shi L, Ding W, Li D, Wang Z, Jiang H, Zhang J, et al. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis. 2006;188:260–264
  74. Watanabe T, Suguro T, Kanome T, Sakamoto Y, Kodate S, Hagiwara T, et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension. 2005;46:738–744
  75. Joyal D, Huynh T, Aiyar N, Guida B, Douglas S, Giaid A. Urotensin-II levels in acute coronary syndromes. Int J Cardiol. 2006;108:31–35
  76. Gruson D, Rousseau MF, Ahn SA, van Linden F, Ketelslegers JM. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides. 2006;27:1527–1531
  77. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation. 2002;106:2877–2880
  78. Richards , Nicholls MG, Lainchbury JG, Fisher S, Yandle TG. Plasma urotensin II in heart failure. Lancet. 2002;360:545–546
  79. Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P, et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol. 2003;285:H1576–H1581
  80. Heringlake M, Kox T, Uzun O, Will B, Bahlmann L, Klaus S, et al. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept. 2004;121:129–136
  81. Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol. 2001;132:5–9
  82. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Circulation. 2001;104:2996–3007
  83. Zou Y, Nagai R, Yamazaki T. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett. 2001;508:57–60
  84. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res. 2003;93:246–253
  85. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin-II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol. 2004;18:2344–2354
  86. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet. 2002;359:1990–1997
  87. Lapp H, Boerrigter G, Costello-Boerrigter LC, Jaekel K, Scheffold T, Krakau I, et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol. 2004;94:93–97
  88. Zhou P, Wu SY, Yu CF, Wang H, Tang CS, Lin L, et al. Effects of urotensin II on isolated rat hearts under normal perfusion and ischemia reperfusion. Sheng Li Xue Bao. 2003;55:442–448
  89. Russell FD, Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc Res. 2004;63:673–681
  90. Zhang Y, Li J, Cao J, Chen J, Yang J, Zhang Z, et al. Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels. 2002;16:64–68
  91. Khan SQ, Bhandari SS, Quinn P, Davies JE, Ng LL. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol. 2007;117:323–328
  92. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P, Malatino L. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Kidney Int. 2006;69:1253–1258
  93. Saetrum OO, Nothacker H, Ehlert FJ, Krause DN. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol. 2000;406:265–271
  94. Tasaki K, Hori M, Ozaki H, Karaki H, Wakabayashi I. Mechanism of human urotensin II-induced contraction in rat aorta. J Pharmacol Sci. 2004;94:376–383
  95. Rossowski WJ, Cheng BL, Taylor JE, Datta R, Coy DH. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol. 2002;438:159–170
  96. Wang YX, Ding YJ, Zhu YZ, Shi Y, Yao T, Zhu YC. Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. Am J Physiol Heart Circ Physiol. 2007;292:H348–H359
  97. Matsusaka S, Wakabayashi I. Enhancement of vascular smooth muscle cell migration by urotensin II. Naunyn Schmiedebergs Arch Pharmacol. 2006;3735:381–386
  98. Tamura K, Okazaki M, Tamura M, Isozumi K, Tasaki H, Nakashima Y. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci. 2003;72:1049–1060
  99. Itoh H, McMaster D, Lederis K. Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur J Pharmacol. 1988;149:61–66
  100. Coy DH, Rossowski WJ, Cheng BL, Taylor JE. Structural requirements at the N-terminus of urotensin II octapeptides. Peptides. 2002;23:2259–2264
  101. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure–activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem. 2002;45:1799–1805
  102. Grieco P, Carotenuto A, Patacchini R, Maggi CA, Novellino E, Rovero P. Design, synthesis, conformational analysis and biological studies of urotensin-II lactam analogues. Bioorg Med Chem. 2002;10:3731–3739
  103. Kinney WA, Almond HR, Qi J, Smith CE, Santulli RJ, de Garavilla L, et al. Structure–function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Ed Engl. 2002;41:2940–2944
  104. Grieco P, Carotenuto A, Campiglia P, Zampelli E, Patacchini R, Maggi CA, et al. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J Med Chem. 2002;45:4391–4394
  105. Croston GE, Olsson R, Currier EA, Burstein ES, Weiner D, Nash N, et al. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954). J Med Chem. 2002;45:4950–4953
  106. Behm DJ, Herold CL, Ohlstein EH, Knight SD, Dhanak D, Douglas SA. Pharmacological characterization of SB-710411 (Cpa-c[d-Cys-Pal-d-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br J Pharmacol. 2002;137:449–458
  107. Herold CL, Behm DJ, Buckley PT, Foley JJ, Wixted WE, Sarau HM, et al. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. Br J Pharmacol. 2003;139:203–207
  108. Dhanak D, Knight SD. Urotensin-II receptor antagonists. 2001;WO/2001/0145694
  109. Dhanak D, Knight SD, Jim J, Keenan RM. Urotensin-II receptor antagonists. 2001;WO/2001/45711
  110. Tarui N, Santo T, Mori M, Watanabe H. Vasoactive agents. 2001;W/2001/66143]
  111. Tarui N, Santo T, Watanabe H, Aso K, Miwa T, Takekawa S. Biphenyl compound. 2002;WO/2002/00606
  112. Tarui N, Santo T, Watanabe K, Aso K, Ishhara Y. GPR14 antagonist. 2002;WO/2002/02530
  113. Aissaoui H, Binkeret C, Clozel M, Mathys B, Mueller C, Nayler O, et al. Preparation of 1,2,3,4-tetrahydroisoquinolinyl ureas and related derivatives as urotensin II receptor antagonists. 2002;WO/2002/76979
  114. Dhanak D, Knight SD, Jim J, Keenan RM. reparation of N-(2-quinolinyl)propane-1,3-diamines as urotensin-II receptor antagonists. 2002;WO/2002/58702
  115. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, et al. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther. 2004;311:204–212
  116. Douglas SA. Human urotensin-II as a novel cardiovascular target: ‘heart’ of the matter or simply a fishy ‘tail’?. Curr Opin Pharmacol. 2003;3(2):159–167
  117. Patacchini R, Santicioli P, Giuliani S, Grieco P, Novellino E, Rovero P, et al. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol. 2003;140:1155–1158
  118. Douglas SA, Dhanak D, Johns DG. From ‘gills to pills’: urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci. 2004;25:76–85
  119. Clozel M, Hess P, Qiu C, Ding SS, Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther. 2006;316:1115–1121
  120. Bousette N, Hu F, Ohlstein EH, Dhanak D, Douglas SA, Giaid A. .Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol. 2006;41:285–295
  121. Bousette N, Pottinger J, Ramli W, Ohlstein EH, Dhanak D, Douglas SA, et al. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides. 2006;27:2919–2926
  122. Bousette N, Giaid A. Urotensin-II and cardiovascular diseases. Curr Hypertens Rep. 2006;8:479–483
  123. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krähenbühl S, et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther. 2006;80:246–256
  124. Pakala R, Leborgne L, Cheneau E, Chen RC, Yazdi H, Fournanadjiev J, et al. Radiation-induced atherosclerotic plaque progression in a hypercholesterolemic rabbit: a prospective vulnerable plaque model?. Cardiovasc Radiat Med. 2003;4:146–151
  125. Pakala R, Dilcher C, Baffour R, Hellinga D, Seabron R, Joner M, et al. Peroxisome proliferator-activated receptor g ligand pioglitazone alters neointimal composition in a balloon-denuded and radiated hypercholesterolemic rabbit. J Cardio Vasc Pharmacol. 2006;48:299–305

PII: S1553-8389(08)00008-0

doi: 10.1016/j.carrev.2008.02.001

Cardiovascular Revascularization Medicine
Volume 9, Issue 3 , Pages 166-178 , July 2008

Article Tools

* Image Usage & Resolution